Evofem Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Operations
(In thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net income (loss) | $391 | $(8,860) |
| Other comprehensive income (loss): | ||
| Change in fair value of financial instruments attributed to credit risk change (Note 4) | (6,188) | (1,924) |
| Reclassification adjustment related to debt extinguishment | - | 143 |
| Comprehensive loss | $(5,797) | $(10,641) |
See accompanying notes to consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.